 |
144 Diseases |  |
5 Trials |
|
5 Trials |  |
861 News |  |
| «123456789» |
- | imetelstat (JNJ-63935937) / Geron
Any thoughts about imetelstat? (Twitter) - Mar 19, 2021
- || imetelstat (JNJ-63935937) / Geron
Clinical, Journal, IO biomarker: Myelosuppression in Patients Treated with the Telomerase Inhibitor Imetelstat Is Not Mediated through Activation of Toll-Like Receptors. (Pubmed Central) - Mar 12, 2021
Furthermore, imetelstat treatment of the MPN cell line HEL did not impact the expression of TLR signaling pathway target genes that are commonly induced by activation of different TLRs, whereas it significantly reduced its target gene hTERT, human telomerase reverse transcriptase, in a dose- and time-dependent manner. Hence, cytopenias, especially thrombocytopenia observed in some patients treated with imetelstat, are not mediated by off-target interactions with TLRs.
- ||| imetelstat (JNJ-63935937) / Geron
Imetelstat is the cure (Twitter) - Mar 9, 2021
- |||| imetelstat (JNJ-63935937) / Geron
#ASH20 | Phase II study shows durable transfusion independence with Imetelstat in lower-risk #myelodysplasticsyndrome https://t.co/2C9RZnMH5O #MDSsm #MDS @DavidSteensma @UP11558193 (Twitter) - Feb 6, 2021
- || Revlimid (lenalidomide) / BMS
Clinical, Review, Journal: Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options. (Pubmed Central) - Feb 4, 2021
Furthermore, several novel agents are currently in development to address this area of clinical need such as imetelstat and roxadustat. In this article, we review the currently available therapeutic options for symptomatic anemia in LR-MDS as well as review the therapeutic agents in development.
- ||||| imetelstat (JNJ-63935937) / Geron
Clinical, Review: #kuashreview @KUcancercenter Dr. Yacoub @AYACOUB7 discuss clinical trial of Imetelstat in RR MF (Twitter) - Jan 23, 2021
- | imetelstat (JNJ-63935937) / Geron
F when imetelstat gonna be approved People dying!!! (Twitter) - Jan 22, 2021
- ||| imetelstat (JNJ-63935937) / Geron
Cancer moonshot imetelstat $gern (Twitter) - Jan 22, 2021
- | Journal: Investigational non-JAK inhibitors for chronic phase myelofibrosis. (Pubmed Central) - Jan 21, 2021
Drugs that target new molecular pathways (MDM2, p-selectin, TIM-3, Bcl-2, TGF-β, aurora kinase) and immune-based strategies (CALR vaccine, anti-PD-1, allogeneic cord blood regulatory T cells) are in early phase trials. Further translational studies to target leukemic stem cells, improvement in trial designs by incorporating control arm and survival endpoints, and patient-focused collaborations among all stakeholders could pave a way for future success in MF drug development.
- || imetelstat (JNJ-63935937) / Geron
When will imetelstat get approval? Lives depend on it (Twitter) - Jan 19, 2021
- |||| imetelstat (JNJ-63935937) / Geron
Clinical: Thank you! Constitutional TL may influence overall hematopoietic function: patients with shorter telomere length had worse cytopenias. Imetelstat may inhibit telomere maintenance and growth preferentially in MDS clones, supporting non-malignant hematopoiesis in LR MDS patients. (Twitter) - Jan 10, 2021
- ||||| imetelstat (JNJ-63935937) / Geron
Clinical: Great study, how do you explain that telomerase inhibitors like imetelstat seem to improve anemia in lower risk MDS patients? (Twitter) - Jan 9, 2021
- | imetelstat (JNJ-63935937) / Geron
Journal: JAK2 inhibition in JAK2-bearing leukemia cells enriches CD34 leukemic stem cells that are abolished by the telomerase inhibitor GRN163L. (Pubmed Central) - Jan 6, 2021
JAK2 inhibitors thus cause enrichment of LSCs and are unlikely to cure MPN as a monotherapy. Simultaneously targeting JAK2V617F and KLF4 or telomerase may be a novel strategy for MPN therapy, which should be of significance both biologically and clinically.
- || Clinical, Review, Journal, IO biomarker: Telomerase-based cancer therapeutics: a review on their clinical trials. (Pubmed Central) - Jan 1, 2021
Many of these therapeutic tools are under different stages of clinical trials and have shown promising outcomes. In this review, we highlight the current status of telomerase-based cancer therapeutics and the outcome of these investigations.
- || imetelstat (JNJ-63935937) / Geron
FDA event: Imetelstat needs to be approved asap. The fda is killing people. $gern (Twitter) - Dec 30, 2020
- |||||| Rytelo (imetelstat) / Geron
Enrollment open, Trial initiation date: IMpactMF: A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment (clinicaltrials.gov) - Dec 23, 2020
P3, N=320, Recruiting, Sponsor: Geron Corporation
In this review, we highlight the current status of telomerase-based cancer therapeutics and the outcome of these investigations. Not yet recruiting --> Recruiting | Initiation date: Mar 2021 --> Dec 2020
- || imetelstat (JNJ-63935937) / Geron
Don't worry, your immune. You've been exposed to imetelstat. 😊 (Twitter) - Dec 20, 2020
- ||| imetelstat (JNJ-63935937) / Geron
Clinical, Review: Imetelstat for patients with RBC transfusion-dependent, ESA-R/R, lower-risk #MDS, demonstrated a predictable safety profile and induced durable and clinically meaningful responses. Review the IMerge trial results reported by @DavidSteensma et al. #mdssm https://t.co/2C9RZnMH5O (Twitter) - Dec 18, 2020
- ||| imetelstat (JNJ-63935937) / Geron
What a wonderful commentary by @MikkaelSekeres! On the use of first in class Telomerase inhibitor (Imetelstat) in lower-risk non-del5q MDS @DavidSteensma. Summarizes the Paradox in #MDSsm https://t.co/E3fhM94rIi (Twitter) - Dec 10, 2020
- ||| imetelstat (JNJ-63935937) / Geron
The accompanying article @DavidSteensma to the editorial https://t.co/1nqp0bhhR3 encouraging results of imetelstat in LR MDS #mdssm #leusm (Twitter) - Dec 9, 2020
- ||| imetelstat (JNJ-63935937) / Geron
Insightful parsing on the positioning of imetelstat in the LR MDS landscape @MikkaelSekeres @ASCO_pubs #leusm https://t.co/9qzWgtRiSu (Twitter) - Dec 9, 2020
- || imetelstat (JNJ-63935937) / Geron
Great commentary in JCO on Imetelstat in MDS by @MikkaelSekeres . This really puts drug development and emerging treatments in low-risk MDS in perspective 👏 #MDS (Twitter) - Dec 9, 2020
- || imetelstat (JNJ-63935937) / Geron
Fantastic work by Dr.Mascarenhas on imetelstat, time to raise the bar in MF and use OS as an endpoint? To quote @doctorpemm. #ASH2020 (Twitter) - Dec 6, 2020
- |||| imetelstat (JNJ-63935937) / Geron
Clinical: Important findings with @imetelstat for MF patients with the worse prognosis, triple-negative or harboring high molecular risk mutations @Ramikomrokji #ASH20 https://t.co/4ZQriMCu0P (Twitter) - Dec 6, 2020
- ||||| imetelstat (JNJ-63935937) / Geron
Clinical: Analysis of relation of cytogenetic and pathological changes to outcomes of patients treated with Imetelstat @jjkiladjian @Ramikomrokji #mpnsm #ASH2020 (Twitter) - Dec 6, 2020
- ||||| imetelstat (JNJ-63935937) / Geron
Clinical: #ASH20 Dr John Mascarenhas #MPNSM oral session demonstrating potential OS improvement in patients with R/R MF treated with #Imetelstat at dose of 9.4 mg/kg (N=59) #ASHFromHome @mpndoc @lauracmichaelis @kristenpettitmd (Twitter) - Dec 6, 2020
- ||||| imetelstat (JNJ-63935937) / Geron
Clinical: Paper: Favorable Overall Survival with Imetelstat Treatment Correlates with Other Clinical Benefits in Intermediate 2 or High Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor @jjkiladjian #MPNSM https://t.co/zXRj94a4e6 (Twitter) - Dec 5, 2020
- ||||| imetelstat (JNJ-63935937) / Geron
Clinical: #ASH20 | ***Important slide by Dr John Mascarenhas in oral #MPNSM session 👉 highlights new study design for Ph3 #IMpactMF randomized #Imetelstat vs #BAT : importantly #PrimaryEndpoint is #OverallSurvival 👉 marking a new moment in our MPN field. @mpndoc @lauracmichaelis @mpdrc (Twitter) - Dec 5, 2020
- ||||| imetelstat (JNJ-63935937) / Geron
Clinical: Benefits in survival of patients with #myelofibrosis treated with imetelstat correlates with reduction of fibrosis in the bone marrow #ASH20 #MPNsm (Twitter) - Dec 5, 2020
- |||||| imetelstat (JNJ-63935937) / Geron
Clinical: #ASH20 MPN oral session. Fantastic & important talk Dr John Mascarenhas on #Imetelstat #TelomeraseInhibitor for patients with MF. #MPNSM @ASH_hematology #ASHKudos #ASHFromHome (Twitter) - Dec 5, 2020
- ||||| imetelstat (JNJ-63935937) / Geron
Clinical, P3 data: Good friend Dr Mascarenhas sharing the potential impact of imetelstat on survival in R/R MF patients soon to be potentially confirmed in a Phase 3 clinical trial. #ASHFromHome #mpnsm @UTHealthSAMDA (Twitter) - Dec 5, 2020
- ||||| imetelstat (JNJ-63935937) / Geron
Clinical: 🆕 results from phase 2 multicenter study shows that imetelstat confers durable transfusion independence in patients with lower-risk myelodysplastic syndrome https://t.co/oaM7XCe0BN study led by @DavidSteensma David P. Steensma, MD @harvardmed (Twitter) - Dec 2, 2020
- | imetelstat (JNJ-63935937) / Geron
Imetelstat is next $gern (Twitter) - Nov 12, 2020
- || imetelstat (JNJ-63935937) / Geron
Have you tried imetelstat? (Twitter) - Nov 6, 2020
- imetelstat (JNJ-63935937) / Geron
[VIRTUAL] Treatment with Imetelstat Provides Durable Transfusion Independence (TI) in Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs) (Channel 15 (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_4448;
P2/3
Imetelstat achieved an 8-w TI rate of 42% for a median duration of 20 mo, the longest so far reported with any agent in non-del 5q LR-MDS, and 29% of pts achieved TI ≥ 1 y. Furthermore, a high and durable HI-E rate (68% for median of 21 mo) was also achieved in this population of heavily RBC TD, ESA-R/R LR-MDS. Enrollment is ongoing in the Phase 3 portion of IMerge, a placebo-controlled trial of the efficacy and safety of imetelstat, including potential predictive biomarkers of response.
- imetelstat (JNJ-63935937) / Geron
[VIRTUAL] Imerge: A Phase 3 Study to Evaluate Imetelstat in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_3911;
P2/3
Biomarkers relevant to the mechanism of action of imetelstat will be assessed to demonstrate target inhibition and their association with clinical responses. Cytogenetics and mutation analyses will be performed to evaluate the impact of imetelstat on reduction/depletion of malignant clones leading to disease modification.
- imetelstat (JNJ-63935937) / Geron
[VIRTUAL] Treatment with Imetelstat Improves Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in Patients with Relapsed or Refractory Higher-Risk Myelofibrosis (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_3886;
P2
TSS symptom responders treated with imetelstat 9.4 mg/kg also had improvement in QoL as measured by EORTC QLQ-C30. The data further support the robustness of overall and individual symptom improvement in pts with MF as evidenced by the correlation of modified MFSAF v2.0 with other PROs such as EORTC QLQ-C30, PGIC, and BP-I.
- imetelstat (JNJ-63935937) / Geron
[VIRTUAL] Imetelstat Treatment Results in Clinical Benefits, Including Improved Overall Survival, in Patients with Higher-Risk Triple-Negative Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitors (JAKi) (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_3882;
P2
Furthermore, TN pts had shorter TL and higher hTERT levels at baseline, representing a suitable target population for telomerase inhibitor treatment. These data warrant further investigation of imetelstat in a clinical trial in TN pts who have limited treatment options.
- imetelstat (JNJ-63935937) / Geron
[VIRTUAL] Telomerase Activity, Telomere Length and hTERT Expression Correlate with Clinical Outcomes in Higher-Risk Myelofibrosis (MF) Relapsed/Refractory (R/R) to Janus Kinase Inhibitor Treated with Imetelstat (Channel 15 (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_3073;
P2
Improved clinical outcomes were noted in pts with shorter telomeres and high hTERT expression. These data are consistent with telomere biology in cancer cells and provide evidence for on-target mechanism of action of imetelstat through telomerase inhibition.
- imetelstat (JNJ-63935937) / Geron
[VIRTUAL] Potential Disease-Modifying Activity of Imetelstat Demonstrated By Reduction in Cytogenetically Abnormal Clones and Mutation Burden Leads to Clinical Benefits in Relapsed/Refractory Myelofibrosis Patients (Channel 15 (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_3072;
P2
Significant dose-dependent reductions of mutation burden by imetelstat were noted and correlated with improved overall clinical benefits including higher rates of spleen and symptom responses, bone marrow fibrosis improvement, and prolonged OS. Together with the clinical data that suggest improvement in median OS in these pts, the data presented here further demonstrate that imetelstat has disease-modifying activity by targeting malignant cells, as evidenced by depletion of cytogenetically abnormal clones and reduction in mutation burden.
- imetelstat (JNJ-63935937) / Geron
[VIRTUAL] A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK) Inhibitor (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_2658;
Ruxolitinib, a Janus kinase 1 (JAK1)/Janus kinase 2 (JAK2) inhibitor and fedratinib, a JAK2/FLT3 inhibitor, are the only approved treatment options for MF...Patients randomized to BAT will receive investigator-selected therapy, which may include hydroxyurea, thalidomide, interferon, danazol, hypomethylating agents, chemotherapy, or other non-JAK inhibitor containing therapy as appropriate in this setting...Mutation analyses will be performed to evaluate the impact of imetelstat on reduction/depletion of malignant clones leading to disease modification. The study will be conducted at approximately 150 centers in North and South America, Europe, Asia, and Middle East.
- imetelstat (JNJ-63935937) / Geron
[VIRTUAL] Aberrant Telomere Length and Composition Are Recurrent Features of Myeloid Disorders (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_1918;
Our findings provide a rationale for (1) the use of WGS to investigate TL, (2) the fundamental discovery that TL shortening is a common principle in myeloid neoplasms, (3) TP53 mutations being accompanied with increased TL and (4) the exploitation of TL to identify subgroups eligible for treatment with imetelstat. Moreover, WGS-based TL analysis in leukemias can contribute to our understanding of TL maintenance mechanisms in leukemic genome.
- imetelstat (JNJ-63935937) / Geron
[VIRTUAL] Favorable Overall Survival with Imetelstat Treatment Correlates with Other Clinical Benefits in Intermediate 2 or High Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor (Channel 15 (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_1679;
P2
These data show dose-related improvement in OS with imetelstat in pts who are R/R to JAKi. The potential survival benefit observed with imetelstat was supported by the trend of correlation with other clinical benefits and warrants further clinical study.
- imetelstat (JNJ-63935937) / Geron
[VIRTUAL] Correlation Analyses of Imetelstat Exposure with Pharmacodynamic Effect, Efficacy and Safety in a Phase 2 Study in Patients with Higher-Risk Myelofibrosis Refractory to Janus Kinase Inhibitor Identified an Optimal Dosing Regimen for Phase 3 Study (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_1070;
P2
Imetelstat 9.4 mg/kg every 21 days treatment yielded higher exposure, leading to higher rate of pts achieving the optimal PD effect, consistently better clinical benefits, such as higher symptom response and significantly longer median OS, and had a similar safety profile as 4.7 mg/kg with regard to hematologic and liver function parameters. This exposure-response analysis of benefit/risk profile supports 9.4 mg/kg every 21 days as the optimal dosing regimen for the planned imetelstat Phase 3 study in refractory MF.
- imetelstat (JNJ-63935937) / Geron
[VIRTUAL] Imetelstat Inhibits Telomerase and Prevents Propagation of ADAR1-Activated Myeloproliferative Neoplasm and Leukemia Stem Cells (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_1049;
Finally, RNA-seq analysis performed on human CD34+ cells from imetelstat treated LSC mouse models revealed a significant reduction in LSC harboring malignant ADAR1-mediated A-to-I editing at doses that spared normal hematopoietic stem cells. CONCLUSIONS Combined WGS and RNA-Seq analyses, lentiviral ADAR1 overexpression, stromal co-culture assays and humanized pre-LSC and LSC mouse model studies reveal that pre-LSC evolution into LSC coincides with both ADAR1 and hTERT activation, which can be prevented with imetelstat.
- |||| imetelstat (JNJ-63935937) / Geron
Clinical: Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion–Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study https://t.co/MWuXGTeLgO (Twitter) - Nov 4, 2020
- ||| imetelstat (JNJ-63935937) / Geron
FDA event: In your opinion do you think Imetelstat will get FDA approval? $gern (Twitter) - Oct 28, 2020
- ||| imetelstat (JNJ-63935937) / Geron
Clinical: Our MDS3001 trial of imetelstat in transfusion dependent #MDS pts is now online @JCO_ASCO: 37% 8-week RBC TI rate, slightly higher rate in HMA/len-naive subset, a number of patients had reduction in clone size during treatment. Phase 3 ongoing. $GERN https://t.co/bSqjWI873R (Twitter) - Oct 28, 2020
- || Clinical, Review, Journal: Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms. (Pubmed Central) - Oct 21, 2020
Janus kinase (JAK) inhibition forms the cornerstone of the treatment of myelofibrosis (MF), and the JAK inhibitor ruxolitinib is often used as a second-line agent in patients with polycythemia vera (PV) who fail hydroxyurea (HU)...JAK inhibitor-based combinations, all of which are currently under study for MF, have been covered elsewhere in this issue. In this article, we focus on agents that have been studied as monotherapy in patients with MF, generally after JAK inhibitor resistance/intolerance, as well as several novel compounds in development for PV/ET.